All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
The NMPA accepted a BLA from Astellas Pharma Inc. for enfortumab vedotin, which is designed for the treatment of patients with locally advanced or metastatic urothelial cancer who previously received treatment with a PD-1/L1 inhibitor and platinum-based chemotherapy.
Fibrogen Inc. has synthesized inhibitors of lysine-specific demethylase 5 (KDM5), particularly KDM5B (JARID1B), reported to be useful for the treatment of cancer, anxiety disorder, schizophrenia, viral infection, bipolar disorder, autism, Alzheimer's and Huntington's diseases, among others.
CSPC Megalith Biopharmaceutical Co. Ltd. has disclosed antibody-drug conjugates comprising a humanized monoclonal antibody targeting nectin-4 covalently linked to cytotoxic agents through a linker. They are reported to be useful for the treatment of cancer.
Coimmune Inc. has exercised its option to obtain an exclusive license to IL-18 armored chimeric antigen receptor (CAR) technology under a prior agreement with Memorial Sloan Kettering Cancer Center (MSK). The company plans to couple the technology with allogeneic cytokine induced killer (CIK) cells to launch the clinical development of CMN-008 (armored CAR-CIK cells), with CD19 as the initial target in B-cell malignancies.
Lift Biosciences Ltd. has released preclinical data demonstrating that its immunomodulatory alpha neutrophil product (IMANp) possesses both cytotoxic and immunomodulatory functionalities that could signal its potential to cure solid tumors. IMANp is generated from the hematopoietic stem cells of donors with exceptional anticancer innate immunity.